Literature DB >> 8667864

Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. UK Haemophilia Centre Directors' Organisation.

S C Darby1, D W Ewart, P L Giangrande, R J Spooner, C R Rizza.   

Abstract

BACKGROUND: Greater age at infection with HIV-1 is known to be associated with shorter time to development of AIDS, but the size of the differences between people infected in infancy and those infected in old age has not been examined in a single large population of patients with death as an endpoint. We, therefore, investigated the role of age at seroconversion in the entire UK population of haemophiliacs.
METHODS: We studied 1216 HIV-1-infected haemophilia patients in the UK who were registered with the National Haemophilia Register and were alive on Jan 1, 1985. Their estimated ages at HIV-1 seroconversion ranged from 8 months to 79 years.
FINDINGS: 10 years after seroconversion 67% (95% Cl 64-69) of the population were still alive. Survival was strongly related to age at seroconversion (86% [82-90], 72% [68-76], 45% [39-51], and 12% [5-21] at 10 years among those patients who seroconverted at ages < 15, 15-34, 35-54, and > or = 55). This steep age-gradient in survival was not explained by deaths expected in the absence of HIV infection or by confounding with other factors such as haemophilia type or severity. The age-gradient was steeper for survival (ie, time from HIV-1 infection to death) than for time to diagnosis of AIDS, partly because survival after an AIDS diagnosis was poorer in older patients, and there was also a substantial increase in mortality among HIV-infected patients who did not satisfy the formal AIDS definition and this increase was greater in older patients.
INTERPRETATION: Age at infection with HIV-1 is a more important determinant of survival than has previously been appreciated. Age should, therefore, be considered in future studies of disease progression, and studies that compare people infected at different ages should provide insight into the biology of the immune response to HIV-1.

Entities:  

Mesh:

Year:  1996        PMID: 8667864     DOI: 10.1016/s0140-6736(96)91073-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  28 in total

1.  Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.

Authors:  S I Staprans; P J Dailey; A Rosenthal; C Horton; R M Grant; N Lerche; M B Feinberg
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 2.  A challenge for the future: aging and HIV infection.

Authors:  Tammy M Rickabaugh; Beth D Jamieson
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

3.  Circumstances at HIV diagnosis and progression of disease in older HIV-infected Americans.

Authors:  D S Zingmond; N S Wenger; S Crystal; G F Joyce; H Liu; U Sambamoorthi; L A Lillard; A A Leibowitz; M F Shapiro; S A Bozzette
Journal:  Am J Public Health       Date:  2001-07       Impact factor: 9.308

4.  HIV infection in older adults in sub-Saharan Africa: extrapolating prevalence from existing data.

Authors:  Joel Negin; Robert G Cumming
Journal:  Bull World Health Organ       Date:  2010-08-27       Impact factor: 9.408

5.  Aging in AIDS; AIDS and aging.

Authors:  A C Justice; C Whalen
Journal:  J Gen Intern Med       Date:  1996-10       Impact factor: 5.128

6.  Recent aspects of HIV and HIV-related diseases.

Authors:  L Gürtler
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

7.  Survival and progression of HIV disease in women attending GUM/HIV clinics in Britain and Ireland. Study Group for the MRC Collaborative Study of HIV Infection in Women.

Authors: 
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

Review 8.  Antiretroviral therapy for human immunodeficiency virus infection in 1997.

Authors:  D A Katzenstein
Journal:  West J Med       Date:  1997-05

9.  Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs.

Authors:  Alan Landay; Lorie Benning; James Bremer; Barbara Weiser; Harold Burger; Marek Nowicki; Andrea Kovacs
Journal:  J Infect Dis       Date:  2003-07-01       Impact factor: 5.226

10.  Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.

Authors:  Rita B Effros; Courtney V Fletcher; Kelly Gebo; Jeffrey B Halter; William R Hazzard; Frances McFarland Horne; Robin E Huebner; Edward N Janoff; Amy C Justice; Daniel Kuritzkes; Susan G Nayfield; Susan F Plaeger; Kenneth E Schmader; John R Ashworth; Christine Campanelli; Charles P Clayton; Beth Rada; Nancy F Woolard; Kevin P High
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.